Pneumococcal polysaccharide conjugate vaccine (13-Valent, Adsorbed): A guide to its use in older adults

Drugs and Aging

Volumn 29, Issue 10, 2012, Pages 847-855

  Scott, Lesley J ^a   Sanford, Mark ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PPV23 VACCINE; PREVENAR 7; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANOREXIA; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILL; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; ERYTHEMA MULTIFORME; FATIGUE; HEART FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MYALGIA; PERITONITIS; PRIORITY JOURNAL; RASH; REVACCINATION; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VOMITING;

AGED; BACTERIAL VACCINES; HUMANS; POLYSACCHARIDES; PRACTICE GUIDELINES AS TOPIC; SAFETY; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84874595165     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0017-0     Document Type: Article

References (24)

1. Lynch JP III, Zhanel GC. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010;16(3):217-25.
2. Annual epidemiological report 2011: reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: European Centre for Disease Prevention and Control; Nov 2011.
3. Paradiso PR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis. 2012;55(2):259-64.
4. Song J-H, Thamlikitkul V, Hsueh P-R. Clinical and economic burden of community-acquired pneumonia among adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38(2):108-17.
5. Isturiz RE, Luna CM, Ramirez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis. 2010;14(10):e852-6.
6. Frenck RW Jr, Yeh S. The development of 13-valent pneumococcal conjugate and its possible use in adults. Expert Opin Biol Ther. 2012;12(1):63-77.
7. Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults. Drugs. 2012;72(9):1243-55.
8. Moberly SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;(1): CD000422.
9. Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48-58.
10. Goldblatt D. Conjugate vaccines. Clin Exp Immunol. 2000;119(1):1-3. (Pubitemid 30064584)
11. Clutterbuck EA, Lazarus R, Yu L-M, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408-16.
12. Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [Prevenar 13®]. Drugs. 2010;70(15):1973-86.
13. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009;374(9700):1543-56.
14. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008;15(47):1328-38.
15. ® suspension for injection (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]): summary of product characteristics. London: European Medicines Agency; 30 May 2012.
16. ® (pneumococcal 13-valent conjugate vaccine [CRM197 protein]); suspension for injection (US prescribing information). Philadelphia (PA): Wyeth Pharmaceuticals Inc; Dec 2011.
17. Jackson L, Gurtman A, van Cleef K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in pneumococcal vaccine naive adults, 50-64 years of age [abstract no. O 426]. In: 21st European Congress of Clinical Microbiology and Infectious Diseases, Milan; 7-10 May 2011.
18. Jackson L, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [abstract no. O 425]. In: 21st European Congress of Clinical Microbiology and Infectious Diseases, Milan; 7-10 May 2011.
19. Schwarz TF, Flamaing J, Rümke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 2011;29(32):5195-202.
20. Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled trial of 13-valent pneumococcal conjugate vaccine given concomitantly with influenza vaccines in healthy adults. Clin Vaccine Immunol. 2012;19(8):1296-303.
21. Greenberg RN, Gurtmann A, Frenck R, et al. A phase 3, randomized, active-controlled trial to evaluate the safety, tolerability, and immunogenicity of sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) administered at 1-year intervals in PPSV23-naive adults 60-64 years of age [abstract no. 665 plus poster). In: 49th Annual Meeting of the Infectious Diseases Society of America, Boston (MA); 20-23 Oct 2011.
22. Advisory Committee on Immunization Practices. Recommendations for pneumococcal vaccine use among immunocompromised adults; meeting notes 20 June 2012. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-jun-2012/04- Pilishvili.pdf. Accessed 17 Sept 2012.
23. Hak E, Grobbee DE, Sanders EAM, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66(9):378-83.
24. Weycker D, Sato R, Strutton D, et al. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine. 2012;30(36):5437-44.